Sleep apnoea is a common condition that requires medical treatment. Non-treatment, non-compliance and low compliance pose serious health risks and push up costs. Poor compliance can generate short-term costs to you as a payor– for equipment used only temporarily and then disposed of or wasted, for instance. In the long run, untreated sleep apnoea carries a risk of major complications and serious co-morbidities.
Getting patients to start, adapt to and continue therapy can depend on a number of issues such as education, proper equipment, training and follow-up as well as support network availability. LISA® is designed with these challenges in mind. We provide a broad selection of treatment devices, masks and accessories from major brands as well as a full range of patient interactive services through homecare or care centres.
For you as a payor, LISA®’s active involvement through homecare or care centres helps to increase patient compliance with treatment. It also supports physicians in tracking progress, identifying compliance issues and taking corrective action.
From a health economics perspective, LISA® has been proven to be an efficient form of therapy offering cost benefits compared with other conservative forms of treatment. A recent systematic review1 and economic analysis study was published in 2009, highlighting that, on average, CPAP offers greater benefits than those achieved with conservative management. The incremental cost per Quality Adjusted Life Year (QALY) gained with CPAP was below £20,000 in the base-case analysis and most alternative scenarios. There was a high probability of CPAP being more cost-effective than dental devices and conservative management for a cost-effectiveness threshold of £20,000 per QALY gained.
¹Continuous positive airway pressure devices for the treatment of obstructive sleep apnoea–hypopnoea syndrome: a systematic review and economic analysis
C McDaid, S Griffin, H Weatherly, K Durée, M van der Burgt, S van Hout, J Akers, R Davies, M Sculpher, and M Westwood.